{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418521471807488.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1089/cbr.2014.1741"}},{"identifier":{"@type":"URI","@value":"http://www.liebertpub.com/doi/full-xml/10.1089/cbr.2014.1741"}},{"identifier":{"@type":"URI","@value":"http://www.liebertpub.com/doi/pdf/10.1089/cbr.2014.1741"}}],"dc:title":[{"@value":"Peptide Receptor Radionuclide Therapy: An Overview"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381418521471807489","@type":"Researcher","foaf:name":[{"@value":"Ashutosh Dash"}],"jpcoar:affiliationName":[{"@value":"Isotope Production and Applications Division, Bhabha Atomic Research Centre, Mumbai, India."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521471807491","@type":"Researcher","foaf:name":[{"@value":"Sudipta Chakraborty"}],"jpcoar:affiliationName":[{"@value":"Isotope Production and Applications Division, Bhabha Atomic Research Centre, Mumbai, India."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521471807488","@type":"Researcher","foaf:name":[{"@value":"Maroor Raghavan Ambikalmajan Pillai"}],"jpcoar:affiliationName":[{"@value":"Molecular Group of Companies, Kochi, India."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521471807490","@type":"Researcher","foaf:name":[{"@value":"Furn F. (Russ) Knapp"}],"jpcoar:affiliationName":[{"@value":"Medical Isotopes Program, Isotope Development Group, Oak Ridge National Laboratory (ORNL), Oak Ridge, Tennessee."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10849785"},{"@type":"EISSN","@value":"15578852"}],"prism:publicationName":[{"@value":"Cancer Biotherapy and Radiopharmaceuticals"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2015-03","prism:volume":"30","prism:number":"2","prism:startingPage":"47","prism:endingPage":"71"},"reviewed":"false","dc:rights":["http://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/"],"url":[{"@id":"http://www.liebertpub.com/doi/full-xml/10.1089/cbr.2014.1741"},{"@id":"http://www.liebertpub.com/doi/pdf/10.1089/cbr.2014.1741"}],"createdAt":"2015-02-24","modifiedAt":"2026-02-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360846643615570688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4"}]},{"@id":"https://cir.nii.ac.jp/crid/1390306894412231936","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"放射性リガンド療法（RLT）と<sup>177</sup>Lu-DOTATATEの臨床的意義および薬剤師の役割"},{"@language":"en","@value":"Clinical Significance of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE and the Role of Pharmacists"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1089/cbr.2014.1741"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.52.1_references_DOI_8OQFwPnXDm3j40VP492unrKII6d"},{"@type":"CROSSREF","@value":"10.1158/1535-7163.mct-16-0040_references_DOI_8OQFwPnXDm3j40VP492unrKII6d"}]}